👉 The AmyFluid is a groundbreaking blood test developed by researchers at the University of California, San Diego, that measures levels of amyloid beta (Aβ) peptides in the blood, which are associated with Alzheimer's disease. Unlike traditional diagnostic methods that rely on imaging or cerebrospinal fluid tests, the AmyFluid offers a non-invasive, cost-effective, and accessible alternative for early detection of Alzheimer's. By analyzing the ratio of different Aβ peptides, the test can indicate whether a person has amyloid plaques in their brain, a hallmark of Alzheimer's pathology, potentially enabling earlier intervention and management of the disease.
